about
Levetiracetam Ameliorates L-DOPA-Induced Dyskinesia in Hemiparkinsonian Rats Inducing Critical Molecular Changes in the StriatumStriatal overexpression of DeltaFosB reproduces chronic levodopa-induced involuntary movementsThe Preclinical Research Progress of Stem Cells Therapy in Parkinson's DiseaseTechnologies for Assessment of Motor Disorders in Parkinson's Disease: A Review.Surgical treatment of Parkinson's disease: patients, targets, devices, and approaches.Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study.Dopamine signaling leads to loss of Polycomb repression and aberrant gene activation in experimental parkinsonismLevodopa-induced dyskinesia is associated with increased thyrotropin releasing hormone in the dorsal striatum of hemi-parkinsonian ratsLong-Term PEG-J Tube Safety in Patients With Advanced Parkinson's DiseaseDopamine agonists in Parkinson's diseaseThe locus coeruleus is directly implicated in L-DOPA-induced dyskinesia in parkinsonian rats: an electrophysiological and behavioural studyThe role of the subthalamic nucleus in L-DOPA induced dyskinesia in 6-hydroxydopamine lesioned ratsA mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicineTowards Real-Time Detection of Freezing of Gait Using Wavelet Transform on Wireless Accelerometer Data.Proteomic analysis of striatal proteins in the rat model of L-DOPA-induced dyskinesia.Presynaptic dopaminergic compartment determines the susceptibility to L-DOPA-induced dyskinesia in ratsMonitoring motor fluctuations in patients with Parkinson's disease using wearable sensors.Reverse microdialysis of a 5-HT2A receptor antagonist alters extracellular glutamate levels in the striatum of the MPTP mouse model of Parkinson's disease.5-HT2A receptor antagonists improve motor impairments in the MPTP mouse model of Parkinson's disease.Efficacy and safety of levodopa-carbidopa intestinal gel from a study in Japanese, Taiwanese, and Korean advanced Parkinson's disease patients.A mouse model of non-motor symptoms in Parkinson's disease: focus on pharmacological interventions targeting affective dysfunctions.MALDI imaging mass spectrometry of neuropeptides in Parkinson's disease.Spontaneous locomotor activity and L-DOPA-induced dyskinesia are not linked in 6-OHDA parkinsonian rats.IRC-082451, a novel multitargeting molecule, reduces L-DOPA-induced dyskinesias in MPTP Parkinsonian primatesMolecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseasesProfile of Mahlon DeLong and Alim Benabid, 2014 Lasker-DeBakey Medical Research awardees.Why are neurotransmitters neurotoxic? An evolutionary perspectiveA Role for Mitogen- and Stress-Activated Kinase 1 in L-DOPA-Induced Dyskinesia and ∆FosB ExpressionDeciphering the Actions of Antiparkinsonian and Antipsychotic Drugs on cAMP/DARPP-32 Signaling.Dopamine regulates distinctively the activity patterns of striatal output neurons in advanced parkinsonian primates.Bladder, bowel, and sexual dysfunction in Parkinson's diseaseα6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.L-DOPA-Induced Dyskinesia and Abnormal Signaling in Striatal Medium Spiny Neurons: Focus on Dopamine D1 Receptor-Mediated Transmission.Present and future drug treatment for Parkinson's disease.Promising cannabinoid-based therapies for Parkinson's disease: motor symptoms to neuroprotectionAnimal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.Clinical aspects and management of levodopa-induced dyskinesia.Design of a single AAV vector for coexpression of TH and GCH1 to establish continuous DOPA synthesis in a rat model of Parkinson's diseaseAbnormal dopaminergic modulation of striato-cortical networks underlies levodopa-induced dyskinesias in humans.
P2860
Q21284508-A36206E3-10E2-4E33-9B59-681DF7EDE434Q24632752-C97FACC3-3E57-46E3-A181-C38925F6B163Q26744445-8CF8A6EF-9DB8-4F8B-A737-A1F57BFD5D9AQ26781340-3FF46340-FAA5-40A1-A064-B6C14C23EE88Q26823204-2678D874-DF46-4493-9037-BB499989A96FQ27303857-C992429E-6059-4F49-ABD0-780245AA7D32Q27313903-BA3FFF21-2A8F-4FA1-8010-84260FD71589Q27316872-A475D2E9-1B7E-4B43-96F0-E388F288136AQ27325443-CC06B4F0-1585-43B1-8265-DF02E48C93DBQ28276692-E093CF97-10CA-4AAF-9076-55AB16067D4AQ28477041-03B770A7-DBA5-483B-B55A-B68BE24659C0Q28482094-99098288-30FF-4A3B-98EA-EEFB66E5A00DQ29547303-9831F363-D3EF-4001-903B-32288FE6B1A8Q31069690-4743A934-E785-4DAC-BC77-4B57C2908DFEQ33285975-236A6906-10F3-4474-8444-8144C069A6D7Q33628372-08129DDD-4FC0-429F-A550-F804ADCDBB37Q33689217-DBFA4DBA-A7B4-4CC7-99CE-8EAFA638C36CQ33763197-C4841BE9-8E38-47E0-8B01-7D2D00341959Q33886545-E9A16444-5885-4793-B262-531AC61451B1Q33917449-E2EC7E49-F2F4-464F-928D-D61E8A5AC811Q34094065-7487428C-8E79-4F33-9558-190CFB215A5EQ34174354-C6A476AB-DD78-4F74-A7EE-88F9DDB4453CQ34279877-00EAF640-5E0E-40D2-ADA3-FAF1D1C868F7Q34542164-FD60D2AF-97C1-4771-859B-B7D163013EFEQ34606186-0635D4B7-83EE-4377-B1D6-1F663BBB2F34Q34752588-C560E055-5C7E-41E2-868C-FEC0EFC869D9Q34885948-070CBBA3-701D-441E-9832-A64E5201899FQ35024117-D6A71DD7-6488-40BD-9B64-8BA8439DC8ACQ35106605-5B3F0666-51FD-476A-97D4-8E871EDF0A70Q35138420-9D73E058-6125-42DA-9C4B-AF24340A2725Q35209869-EAE56579-A12B-4FB1-A2C8-BD26398C1FBEQ35264378-02D530F5-0EB0-4AA6-B8EB-DA8C9D6AEB7EQ35424424-65FCC8C5-4B19-4ABE-A377-0B3E8522A16EQ35484805-F2D1EEBC-EC21-4C80-9BAC-5662155485DDQ35499568-52315250-DCFB-4A45-A284-3F405A7136F1Q35589979-57FF0EE7-4577-4CF5-94EF-2AD5108E2729Q35614156-223336A8-F8AB-4B02-B3CD-2D8B53DBA939Q36022700-BFBCB03D-B698-4871-90CF-2CA9F5B52299Q36085361-7FF88D22-44D1-4222-AAD9-3CF8B95B55B1Q36186759-1D7AE6AA-4305-4862-9906-9546355E8AF4
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Levodopa motor complications in Parkinson's disease.
@ast
Levodopa motor complications in Parkinson's disease.
@en
Levodopa motor complications in Parkinson's disease.
@nl
type
label
Levodopa motor complications in Parkinson's disease.
@ast
Levodopa motor complications in Parkinson's disease.
@en
Levodopa motor complications in Parkinson's disease.
@nl
prefLabel
Levodopa motor complications in Parkinson's disease.
@ast
Levodopa motor complications in Parkinson's disease.
@en
Levodopa motor complications in Parkinson's disease.
@nl
P2093
P1476
Levodopa motor complications in Parkinson's disease.
@en
P2093
P356
10.1016/S1471-1931(00)00031-8
P433
P577
2000-10-01T00:00:00Z